Cargando…
The C4EB study—Transvamix (10% THC / 5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study
Patients with the genetic blistering skin condition epidermolysis bullosa (EB) report severe pain as a consequence of skin and mucous membrane lesions including blisters, wounds, and scars. Adequate symptom alleviation is not often achieved using conventional pharmacologic interventions. Finding nov...
Autores principales: | Schräder, Nicholas H. B., Duipmans, José C., Renken, Remco J., Sörös, Peter, Vermeulen, Karin M., Bolling, Maria C., Wolff, André P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744305/ https://www.ncbi.nlm.nih.gov/pubmed/36508401 http://dx.doi.org/10.1371/journal.pone.0277512 |
Ejemplares similares
-
Novel insights into the epidemiology of epidermolysis bullosa (EB) from the Dutch EB Registry: EB more common than previously assumed?
por: Baardman, R., et al.
Publicado: (2020) -
The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: analysis of clinical outcomes and tumour characteristics in the Dutch EB Registry
por: Harrs, Clara, et al.
Publicado: (2022) -
Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index
por: Schräder, Nicholas H. B., et al.
Publicado: (2021) -
Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study
por: Schräder, Nicholas H. B., et al.
Publicado: (2021) -
Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
por: Schräder, N.H.B., et al.
Publicado: (2018)